|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
gptkb:XYZ_Corp
|
|
gptkbp:awards
|
Best_Biotech_Company_2021
|
|
gptkbp:budget
|
available online
|
|
gptkbp:CEO
|
Jane_Smith
|
|
gptkbp:clinicalTrials
|
ongoing
Phase 1
Phase 2
Phase 3
collaborative studies
|
|
gptkbp:collaborations
|
gptkb:University_of_Science
Health_Institute
|
|
gptkbp:community_engagement
|
educational programs
health fairs
|
|
gptkbp:competitors
|
gptkb:XYZ_Biotech
gptkb:ABC_Biotech
|
|
gptkbp:employees
|
500
|
|
gptkbp:focus
|
gene therapy
|
|
gptkbp:founded
|
gptkb:Boston,_Massachusetts
2000
|
|
gptkbp:founder
|
gptkb:John_Doe
|
|
gptkbp:funding
|
20 million USD
|
|
gptkbp:headquarters
|
gptkb:San_Francisco,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DEF Biotech
|
|
gptkbp:industry
|
Biotechnology
|
|
gptkbp:innovation
|
cutting-edge technology
|
|
gptkbp:investmentFocus
|
gptkb:Venture_Capital_Firm_B
Venture_Capital_Firm_A
|
|
gptkbp:market
|
1 billion USD
global
|
|
gptkbp:mission
|
improve patient outcomes
|
|
gptkbp:partnerships
|
various pharmaceutical companies
|
|
gptkbp:patentCitation
|
over 50
|
|
gptkbp:products
|
biopharmaceuticals
|
|
gptkbp:publications
|
over 100
|
|
gptkbp:regulatoryCompliance
|
FDA_approved
EMA_approved
|
|
gptkbp:research_areas
|
neurology
oncology
immunology
|
|
gptkbp:revenue
|
100 million USD
|
|
gptkbp:services
|
research and development
|
|
gptkbp:social_responsibility
|
community health initiatives
environmental sustainability
|
|
gptkbp:stockExchange
|
DEF
|
|
gptkbp:subsidiary
|
gptkb:DEF_Therapeutics
gptkb:DEF_Diagnostics
|
|
gptkbp:sustainability_initiatives
|
waste reduction programs
green energy use
|
|
gptkbp:trademark
|
DEF_Biotech_Logo
|
|
gptkbp:training
|
leadership training
ongoing development programs
|
|
gptkbp:values
|
gptkb:collaboration
innovation
integrity
excellence
|
|
gptkbp:vision
|
leading biotech innovator
|
|
gptkbp:website
|
www.defbiotech.com
|